Step Pharma shares early Phase II VECTRA trial data for dencatistat in essential thrombocythaemia (ET) ahead of ASH 2026.
Acepodia dosed the first patient in a Phase I trial of ACE723, a GPC3-targeted dual-payload ADC for liver cancer. Read the ...
Moderna's mRNA-2808 yields four confirmed responses in Phase I/II myeloma study targeting BCMA, GPRC5D and FcRH5. Read the ...
Mondego Bio has begun first-in-human dosing of MB-388, an oral PTPN2/PTPN1 inhibitor aimed at overcoming cancer immunotherapy ...
Cambridge spinout T-Therapeutics closes $133m Series B to advance TCR bispecifics in cancer and autoimmune disease. Read the full story for what's next.
Alethio Therapeutics raises USD 90M Series A to advance ATX-011, a G6B antibody for essential thrombocythaemia. Read the ...
Cardiol Therapeutics unveils a USD 75M at-the-market equity program after its MAVERIC Phase III trial met enrollment early.
Emvena Therapeutics launches with seed funding from the Penn-BioNTech PxB Fund to build placenta-targeted mRNA medicines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results